Personal information

cancer immunology, cancer Immunotherapy, T cells, tumor microenvironment, checkpoint inhibition, cellular therapies
Switzerland

Activities

Employment (1)

University of Basel: Basel, Basel, CH

Employment
Source: Self-asserted source
Zippelius A

Education and qualifications (4)

University Hospital of Zurich: Zurich, CH

2007 to present | Clinical Specialization Medical Oncology
Qualification
Source: Self-asserted source
Zippelius A

University of Zurich: Zurich, CH

2006 to present | Habilitation
Qualification
Source: Self-asserted source
Zippelius A

Ludwig-Maximilians-Universität München: Munich, DE

1997 | MD PhD (Immunology)
Qualification
Source: Self-asserted source
Zippelius A

Ludwig Maximilian University of Munich: Munich, DE

1990 to 1997 | MD
Education
Source: Self-asserted source
Zippelius A

Professional activities (7)

University Hospital of Basel: Basel, CH

2023 to present | Co-Chair (Medical Oncology)
Invited position
Source: Self-asserted source
Zippelius A

University Hospital of Basel: Basel, CH

2013 to 2022 | Deputy Chair (Medical Oncology)
Invited position
Source: Self-asserted source
Zippelius A

University Hospital of Basel: Basel, CH

2011 to 2012 | Leading Physician (Medical Oncology)
Invited position
Source: Self-asserted source
Zippelius A

University Hospital of Basel: Basel, CH

2009 to 2010 | Senior Physician (Medical Oncology)
Invited position
Source: Self-asserted source
Zippelius A

University Hospital of Zurich: Zurich, CH

2007 to 2008 | Senior Physician (Medical Oncology)
Invited position
Source: Self-asserted source
Zippelius A

University Hospital of Zurich: Zurich, CH

2004 to 2006 (Resident)
Invited position
Source: Self-asserted source
Zippelius A

Ludwig Maximilian University of Munich: Munich, DE

1997 to 2000 | Resident (Hematology & Oncology)
Invited position
Source: Self-asserted source
Zippelius A

Funding (33)

Spatial Determinants of Immunotherapy Resistance in Cancer

2024 to 2027 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

Dissecting interactions between intratumoral CD8 T cells and other immune cells in pediatric patients with rhabdomyosarcoma

2023 to 2024 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Generation of comprehensive 3D models for personalized medicine

2022 to 2024 | Grant
Roche (Switzerland) (Basel, CH)
Source: Self-asserted source
Zippelius A

Innovation focus Cellular therapies

2021 to 2025 | Grant
University Hospital of Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Understanding metabolic pathways in exhausted T cells

2021 to 2025 | Grant
EU Horizon 2020 Research and Innovation Programme (Brussels, BE)
Source: Self-asserted source
Zippelius A

Deciphering metabolic pathways in exhausted T cells to identify potential targets for the design of novel cancer immunotherapies

2021 to 2024 | Grant
Swiss Cancer League (Bern, CH)
Source: Self-asserted source
Zippelius A

Improvement of tumour-infiltrating lymphocyte expansion for adoptive cell therapy

2021 to 2024 | Grant
HORIZON EUROPE Framework Programme (Brussels, BE)
Source: Self-asserted source
Zippelius A

TCR-QR: Identifying tumour-reactive TCRs for personalized T cell therapies

2021 to 2023 | Grant
Eidgenössische Technische Hochschule Zürich (Zurich, CH)
Source: Self-asserted source
Zippelius A

Dissecting PAI-1 targeted reinvigoration of tumor-specific T cells for early clinical development – a novel approach to improve cancer immunotherapy

2021 to 2022 | Grant
Novartis (Switzerland) (Basel, CH)
Source: Self-asserted source
Zippelius A

Targeting intra-tumoral crosstalk between adaptive and innate immunity in a rationally designed combination approach to enhance cancer immune control

2021 to 2022 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

A 3D-culture platform for in-vitro preclinical Screening of Immunotherapies

2020 to 2023 | Grant
HORIZON EUROPE Framework Programme (Brussels, BE)
Source: Self-asserted source
Zippelius A

Genome-wide CRISPR screen to identify genes involved in T cell dysfunction and novel targets for cancer immunotherapy

2020 to 2023 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

Multidimensional immune profiling of single cells using mass cytometry

2020 to 2020 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

Identification of pharmacodynamic biomarkers associated with PD-1, Tim3 and Lag3 engagement on T cells from checkpoint inhibitor naïve and experienced cancer patients

2019 to 2023 | Grant
Roche (Switzerland) (Basel, CH)
Source: Self-asserted source
Zippelius A

Modelling T cell Dysfunction to Expore Novel Targets for Cancer Immunotherapy

2019 to 2020 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Dissecting the role of GEFH1 in induction of anti-tumor immunity upon treatment with microtubule-targeting chemotherapy in tumor models and cancer patients

2018 to 2019 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Paracrine delivery of therapeutic biologicals: developing new technology for personalized cancer immunotherapy

2017 to 2021 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

Personalized cancer neo-antigen discovery by high-throughput screening of genetically-encoded epitope libraries

2017 to 2021 | Grant
Eidgenössische Technische Hochschule Zürich (Zurich, CH)
Source: Self-asserted source
Zippelius A

Novel Models to Enable TAR001 Clinical Development

2017 to 2019 | Grant
Kommission für Technologie und Innovation (Bern, CH)
Source: Self-asserted source
Zippelius A

Protocol SAKK 16/14: Anti-PD-L1 antibody MEDI4736 in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC), a multicenter single-arm phase II trial

2016 to 2019 | Grant
Gateway for Cancer Research (Schaumburg, US)
Source: Self-asserted source
Zippelius A

Dissecting mechanisms of T cell dysfunction in patients with lung and ovarian cancer

2016 to 2018 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

Targeted immunocytokines to induce anti-tumor immune responses in non-small cell lung cancer

2016 to 2018 | Grant
Krebsliga Schweiz (Bern, CH)
Source: Self-asserted source
Zippelius A

Dissecting anti-tumor immune responses of a novel anti-HER2 anthracycline based antibody drug conjugate in an orthotopic breast cancer model

2016 to 2017 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Dissecting the Immunomodulatory Effects of Novel Anti-Cancer Immunotherapy Agents

2014 to 2018 | Grant
Roche (Switzerland) (Basel, CH)
Source: Self-asserted source
Zippelius A

Harnessing the immune-stimulatory capacities of cytotoxic moities in HER2-directed antibody- drug-conjugates: mechanistic implications for cancer immunotherapy

2014 to 2018 | Grant
Wilhelm Sander Stiftung (Munich, DE)
Source: Self-asserted source
Zippelius A

Harnessing the Immunome’s potential to fight Cancer: Evaluating synergistic antibody drug conjugate – immunotherapy treatments for cancer by comprehensive systems biology analysis

2014 to 2018 | Grant
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

The antibody drug conjugate T-DM1 meets anti-tumor immunit

2014 to 2015 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Anti-tumor immunity upon treatment with chemotherapy and radiotherapy – potential synergism with specific immunotherapy approaches

2011 to 2013 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Generation of cellular reporter systems to monitor the maturation and T-cell stimulatory capacity of dendritic cells upon treatment with anti-tumor therapeutics

2011 to 2012 | Grant
Krebsliga Beider Basel (Basel, CH)
Source: Self-asserted source
Zippelius A

Modulation of specific immunity upon anti-cancer therapy

2010 to 2014 | Award
Swiss National Science Foundation (Bern, CH)
Source: Self-asserted source
Zippelius A

Dissecting anti-tumor immune responses in patients with multiple myeloma: a basis for the development of immuno-therapeutical treatment modalities Principal Investigator, kompetitiv

2004 to 2007 | Grant
Krebsforschung Schweiz (Bern, CH)
Source: Self-asserted source
Zippelius A

Characterization of in vivo anti-tumor immune responses

2003 to 2008 | Grant
Deutsche Forschungsgemeinschaft (Bonn, DE)
Source: Self-asserted source
Zippelius A

Phenotypic and functional characterization of cytotoxic T lymphocytes against melanoma-associated antigens in healthy individuals and in melanoma patients before and after peptide vaccination

2000 to 2003 | Grant
Deutsche Forschungsgemeinschaft (Bonn, DE)
Source: Self-asserted source
Zippelius A

Peer review (8 reviews for 4 publications/grants)

Review activity for Nature cancer. (3)
Review activity for Nature communications (1)
Review activity for Nature medicine. (3)
Review activity for Science translational medicine. (1)